{
    "nct_id": "NCT05840224",
    "official_title": "A Phase 1 Study to Evaluate the Safety and Tolerability of GS-4528 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors",
    "inclusion_criteria": "* Documented disease:\n\n  * Phase 1a dose escalation and backfill cohorts; Phase 1b dose escalation: Individuals with histologically or cytologically confirmed advanced solid tumors who have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy.\n  * Phase 1a dose expansion: Individuals with histologically or cytologically confirmed select indications who have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy.\n* Eastern Cooperative Oncology Group performance status 0 or 1.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.\n* Adequate organ function.\n* Individuals of childbearing potential who engage in heterosexual intercourse must agree to use method(s) of contraception.\n* Tissue requirements:\n\n  * Phase 1a dose escalation, Phase 1a dose expansion, and Phase 1b dose escalation: Must provide pre-treatment adequate tumor tissue sample prior to enrolment.\n  * Phase 1a backfill cohorts: Individuals must have fresh pre-treatment and on-treatment biopsy for biomarker analysis.\n* Life expectancy â‰¥ 3 months.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Positive serum pregnancy test or lactating female.\n* Prohibited concurrent anticancer therapy listed in the protocol.\n* Any anti-cancer therapy, whether investigational or approved, within protocol specified time prior to initiation of study including: major surgery (<28 days), immunotherapy or biologic therapy (< 28 days), chemotherapy (< 21 days), targeted small molecule therapy (< 14 days or < 5 half-lives whichever is shorter), hormonal therapy or other adjunctive therapy (< 14 days) or radiotherapy (< 21 days).\n* Any prior allogeneic tissue/solid organ transplantation, including allogeneic stem cell transplantation.\n* Diagnosis of immunodeficiency, either primary or acquired, or systemic steroid requirement of > 10 mg of prednisone or equivalent.\n* History of intolerance, hypersensitivity, or treatment discontinuation due to severe immune-related adverse events (irAEs) on prior immunotherapy.\n* History of autoimmune disease or active autoimmune disease that has required systemic treatment within 2 years prior to the start of study treatment.\n* Concurrent active second malignancy. Note: Individuals with a history of malignancy that have been completely treated, with no evidence of active cancer for 2 years prior to enrollment, or participants with surgically cured tumors with low risk of recurrence are allowed to enroll.\n* Have known active central nervous system (CNS) metastases and/ or carcinomatous meningitis.\n* Significant cardiovascular disease.\n* Have active serious infection requiring antibiotics.\n* Have active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).\n* History of pneumonitis, interstitial lung disease, or severe radiation pneumonitis (excluding localized radiation pneumonitis).\n* Symptomatic ascites or pleural effusion.\n* Live vaccines within 28 days of initiation of investigational product(s).\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}